

January 15, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, we would like to inform that one of the Subsidiary Company has received an order from Drug Licensing Authority, Drug Control Administration Mahaboobnagar. The details of order are given below:

Name(s) of the Authority :	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s) / contravention(s) committed or alleged to be committed
Assistant Director, Drugs Control Administration, Mahaboobnagar	Suspension of Drug License for 7 days from the Date of Receipt for sale permission premises at Jadcherla	Order dated January 04, 2024 and received on January 12, 2024	Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945

There is no major financial impact. The Company is taking corrective action in this regard.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

